Valuation: Incyte Corporation

Market Cap 24.52B 21.99B 20.27B 18.41B 34.83B 2,299B 35.81B 243B 96.68B 1,232B 92.03B 90.07B 3,894B P/E 2026 *
57.6x
P/E 2027 * 17.1x
Enterprise Value 20.23B 18.14B 16.72B 15.18B 28.73B 1,896B 29.54B 200B 79.75B 1,016B 75.91B 74.3B 3,212B EV / Sales 2026 *
3.34x
EV / Sales 2027 * 2.96x
Free-Float
98.16%
Yield 2026 *
-
Yield 2027 * -
1 day-1.30%
1 week+2.30%
Current month-0.07%
1 month+6.66%
3 months-1.03%
6 months+22.06%
Current year+21.80%
1 week 115
Extreme 115
123.96
1 month 107.78
Extreme 107.7801
123.96
Current year 89.25
Extreme 89.25
132.6
1 year 89.25
Extreme 89.25
132.6
3 years 50.35
Extreme 50.3498
132.6
5 years 50.27
Extreme 50.27
132.6
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
03/11/26 Sell

Principal Accounting Officer

-610 0.0003%
15/10/26 Exercice

Chairperson

7,926 0.0039%
01/10/26 Tax

EVP, Head of Incyte Intl

-463 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-1.30%+2.30%+13.51%+129.41% 24.52B
+1.44%+1.63%+48.17%+139.63% 1,276B
-0.47%+5.49%+49.03%+90.68% 676B
+0.20%+2.76%+34.37%+112.06% 519B
-0.66%+0.91%+38.38%+67.33% 388B
-0.48%+2.34%+70.66%+46.02% 365B
-1.04%-0.76%+28.02%+57.46% 307B
-0.16%-1.11%+2.99%+35.32% 287B
0.00%+0.86%+43.74%+74.04% 252B
+0.92%+2.03%+44.62%+125.07% 212B
Average -0.59%+2.26%+37.35%+87.70% 431B
Weighted average by Cap. -0.72%+2.51%+42.59%+96.75%

Financials

2026 *2027 *
Net sales 6.05B 5.43B 5B 4.54B 8.6B 568B 8.84B 59.9B 23.87B 304B 22.72B 22.24B 961B 6.31B 5.66B 5.21B 4.74B 8.96B 592B 9.21B 62.43B 24.87B 317B 23.68B 23.17B 1,002B
Net income 432M 388M 357M 324M 614M 40.53B 631M 4.28B 1.7B 21.72B 1.62B 1.59B 68.65B 1.45B 1.3B 1.2B 1.09B 2.07B 136B 2.12B 14.4B 5.74B 73.08B 5.46B 5.34B 231B
Net Debt -4.29B -3.85B -3.55B -3.22B -6.1B -403B -6.27B -42.49B -16.93B -216B -16.11B -15.77B -682B -5.82B -5.22B -4.81B -4.37B -8.27B -546B -8.5B -57.59B -22.95B -292B -21.84B -21.38B -924B
Projected Income Statement - Annual - Incyte Corporation
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
10/11/26 $120.30 -1.30% 1,797,816
09/11/26 $121.89 +1.87% 1,154,647
06/11/26 $119.65 +1.39% 1,486,482
05/11/26 $118.01 -3.94% 1,600,119
04/11/26 $122.85 +4.47% 2,140,862
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Incyte Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
120.30USD
Average target price
131.50USD
Spread / Average Target
+9.31%
  1. Stock Market
  2. Stocks
  3. INCY Stock